| Company Name | Bayer Taiwan Co., Ltd |
|---|---|
| Protocol Number | 20590 |
| Title of Study | Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients / DAROL |
| Primary Objective | The purpose of this study is to describe, under real-world conditions, the safety and effectiveness of darolutamide in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) for whom a decision to treat with darolutamide has been made before enrollment. |
| Number of Sites | 5 |
| Period of Study | From：end of February 2022 to：30 Sep 2026 |
| Number of Patients | 25人 |
| IRB Approval Date | CMUH - 2021/10/14 VGHTC - Under Review NTUH - In progress CGMHLK - In progress CGMHKH - In progress |
| Publication Plan / Date | 30 Sep 2026 |
